Survival Efficacy of Combined Radiotherapy and Immunotherapy in Patients With Metastatic Non-small Cell Lung Carcinoma

"The immunotherapy intervention consists of treatment with immune checkpoint inhibitors, specifically Nivolumab (OPDIVO), Atezolizumab (TECENTRIQ), Pembrolizumab (KEYTRUDA).~These drugs are monoclonal antibodies that block PD-1 or PD-L1 pathways, aiming to enhance the immune system's ability to recognize and destroy cancer cells. The treatment is administered intravenously according to standard dosing schedules."

The radiotherapy intervention involves targeted delivery of ionizing radiation to metastatic lesions. Radiotherapy may be given either concurrently with immunotherapy or sequentially afterward, depending on the patient's treatment plan. The purpose is to achieve local tumor control and potentially enhance the systemic immune response through immunogenic cell death. Different radiation techniques and dose regimens may be employed based on lesion size, location, and clinical considerations.